Back to results

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Primary Purpose

Relapsed Multiple Myeloma

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Dexamethasone

Lenalidomide

Carfilzomib

About this trial

This is an interventional treatment trial for Relapsed Multiple Myeloma focused on measuring Multiple Myeloma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Symptomatic multiple myeloma
Measurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization):
- Serum M-protein ≥ 0.5 g/dL
- Urine Bence-Jones protein ≥ 200 mg/24 hours
- For immunoglobulin A (IgA) patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)
Prior treatment with at least one, but no more than three, regimens for multiple myeloma
Documented relapse or progressive disease on or after any regimen
Achieved a response to at least one prior regimen
Age ≥ 18 years
Life expectancy ≥ 3 months
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate hepatic function, with serum alanine aminotransferase (ALT) ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 21 days prior to randomization
Absolute neutrophil count ≥ 1.0 × 10^9/L within 21 days prior to randomization
Hemoglobin ≥ 8 g/dL (80 g/L) within 21 days prior to randomization
Platelet count ≥ 50 × 10^9/L (≥ 30 × 10^9/L if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization
Creatinine clearance (CrCl) ≥ 50 mL/minute within 21 days prior to randomization
Written informed consent in accordance with federal, local, and institutional guidelines
Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception
Male subjects must agree to practice contraception

Exclusion Criteria:

If previously treated with bortezomib (alone or in combination), progression during treatment
If previously treated with a lenalidomide and dexamethasone (len/dex) combination:
- Progression during the first 3 months of initiating treatment
- Any progression during treatment if the len/dex combination was the subject's most recent line of therapy
Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects intolerant to bortezomib are not excluded
Prior carfilzomib treatment
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
Waldenström's macroglobulinemia or IgM myeloma
Plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)
Chemotherapy or investigational agent within 3 weeks prior to randomization or antibody therapy within 6 weeks prior to randomization
Radiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior to randomization; localized radiotherapy to a single site within 7 days prior to randomization
Corticosteroid therapy at a dose equivalent to dexamethasone > 4 mg/day within 21 days prior to randomization
Pregnant or lactating females
Major surgery within 21 days prior to randomization
Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
Known human immunodeficiency virus infection
Active hepatitis B or C infection
Myocardial infarction within 4 months prior to randomization, New York Hear Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization
Other malignancy, including myelodysplastic syndromes (MDS), within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization
Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Ongoing graft-vs-host disease
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Sites / Locations

Mayo Clinic
Providence St. Joseph Medical Center
St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare
Stanford University
Colorado Blood Cancer Institute
Cancer and Blood Disease Center
Rush University Medical Center
Indiana University Health Melvin and Bren Simon Cancer Center
University of Kansas Cancer Center
The University of Michigan - Comprehensive Cancer Center
Mayo Clinic
John Theurer Cancer Center at Hackensack University Medical Center
NYU Clinical Cancer Center
Weill Cornell Medical College
Associates in Oncology and Hematology
The Don & Sybil Harrington Cancer Center
Baylor Sammons Cancer Center
UT Southwestern Medical Center at Dallas
The University of Texas, MD Anderson Cancer Center
Scott and White Memorial Hospital
Fred Hutchinson Cancer Research Center
Froedtert & Medical College of Wisconsin
Medizinische Universitat Wien
Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie
Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
AZ Sint-Jan AV
UZ Brussel
Institut Jules Bordet
Cliniques Universitaires Saint-Luc
UZ Leuven
University Multiprofile Hospital for Active Treatment, "Dr. Georgi Stranski"
University Multiprofile Hospital for Active Treatment "Sveti Georgi"
Military Medical Academy Multiprofile Hospital for Active Treatment
Specialized Hospital for Active Treatment of Hematological Diseases
Multiprofile Hospital for Active Treatment "Sveta Marina"
Tom Baker Cancer Centre
University of Alberta, Cross Cancer Institute
Vancouver General Hospital
Cancer Care Manitoba
General Hospital, Health Sciences Centre
Princess Margaret Hospital
McGill University Health Center, Royal Victoria Hospital
Sir Mortimer B. Davis - Jewish General Hospital
University Hospital Brno, Department of Internal Medicine - Hematooncology
University Hospital Hradec Kralove
University Hospital Olomouc
University Hospital Kralovske Vinohrady - Prague
General University Hospital Prague
Hospital Antoine Beclere
Clinique Victor Hugo - Centre Jean Bernard
Hopital Claude Huriez
CH de Mulhouse, Hopital Emile Muller
CHU Nantes Hotel Dieu
Hopital Saint-Antoine
Groupe Hospitalier Necker - Enfants Malades
Cancer Institut Universitaire de Toulouse-Oncopole (iUCT)
Hopitaux de Brabois
University of Dusseldorf
Krankenhaus Nordwest
University of Hamburg-Eppendorf
Universitat Heidelberg
Stiftungsklinikum Mittelrhein
LMU Klinikum der Universitat
Universitatsklinikum Munster
Universitatsklinikum Wurzburg
Alexandra Hospital
University General Hospital of Patras
St. Istvan and St. Laszlo Hospital of Budapest
University of Debrecen, Medical and Health Science Center
Petz Aladar County Teaching Hospital
Bekes County Pandy Kalman Hospital
Kaposi Mor County Teaching Hospital
University of Pecs
University of Szeged, Albert Szent-Gyorgi Clinical Center
Rambam Medical Center
Hadassah Medical Center, Ein Kerem
Western Gailee Hospital - Nahariya
Rabin Medical Center
The Chaim Sheba Medical Center
Kaplan Medical Center
Azienda Ospedallera Niguarda Ca Granda
Azienda Ospedllero Maggiore della Carita
Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main
Ospedale S. Eugenio
Azienda Ospedaliera Citta della Salute e della Scienza di Torino
Erasmus MC, Department of Haematology
University Clinical Centre, Department of Hematologii Transplantologii
Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp.
Independent Public Teaching Hospital of Medical University of Silesia in Katowice
Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz
Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach
Nicolaus Copernicus Municipal Specialist Hospital
Maria Sklodowska-Curie Institute of Oncology
Zamojski Non-Public Hospital
Fundeni Clinical Institute, "Stefan Berceanu" Center for Hematology and Bone Marrow Transplantation
Coltea Clinical Hospital
Bucharest University Emergency Hospital
Regional Institute of Iasi
State Medical Institution Komi Republican Oncological Center
First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia
Federal State Budgetary Scientific Institution: N.N. Blokhin Russian Cancer Research Center
Moscow State Medical Institution Municipal City Clinical Hospital n.a. S.P. Botkin
Federal State Budget Institution: Hematology Research Center under MoH
FSBI: Russian Research Institute of Hematology and Blood Transfusion under the Ferderal Agency for M&B
State Higher Educational Institution: St Petersburg State Medical University n.a.I.P Pavlov
SHEI: First St. Petersburg State Medical University N.a.I.P Pavlov under MoH, Clinic of Bone Marrow Transplant
Federal State Budget Institute: Federal Almalov Medical Research Centre under Ministry of Healthcare
Clinical Center of Serbia, Clinic of Hematology
Clinical Hospital Center Bezanijska Kosa
Military Medical Academy, Clinic of Hematology
Clinical Center Nis, Clinic of Hematology
Clinical Center of Vojvodina, Clinic of Hematology
Hospital Universitario Germans Trias i Pujol
Hospital Clinic I Provincial
Hospital Universitario de Salamanca
Hospital Donostia
Hospital Universitario y Politeecnico La Fe
Hospital Universitario Miguel Servet
Sahlgrenska Universitetssjukhuset
Karolinska Universitetsjukhuset i Huddinge
Karolinska Universitetssjukhuset Solna, Hematologiskt Centrum
St. Bartholomew's Hospital
Royal Free Hampstead
St. Georges Hospital
Nottingham University Hospitals (City Campus)
Royal Marsden Hospital
The Royal Wolverhampton Hospital NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Lenalidomide and Dexamethasone (Rd)

Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

Arm Description

Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.

Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.

Outcomes

Primary Outcome Measures

Progression-free Survival (PFS)

Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). One or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).

Secondary Outcome Measures

Overall Survival

Overall survival (OS) was defined as the duration from randomization to death due to any cause. Participants who were still alive were censored at the date when the participant was last known to be alive or the data cutoff date, whichever occurred earlier.

Overall Response Rate

Overall response rate is defined as the percentage of participants who achieved either a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).

Disease Control Rate

Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).

Duration of Response

Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.

Duration of Disease Control

Duration of disease control (DDC) was calculated for participants who achieved disease control. DDC was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.

Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores

Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life.

Full Information

NCT ID

NCT01080391

First Posted

March 2, 2010

Last Updated

September 8, 2022

Sponsor

Amgen

1. Study Identification

Unique Protocol Identification Number

NCT01080391

Brief Title

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Official Title

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Study Type

Interventional

2. Study Status

Record Verification Date

September 2022

Overall Recruitment Status

Completed

Study Start Date

July 14, 2010 (Actual)

Primary Completion Date

June 16, 2014 (Actual)

Study Completion Date

December 5, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Amgen

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.

Detailed Description

This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for adults with relapsed multiple myeloma. Eligible subjects will be randomized in a 1:1 ratio to receive either the control Rd or CRd. Randomization will be stratified by β2 microglobulin levels (< vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior lenalidomide (no vs yes). Participants will receive the treatment determined by randomization in 28-day cycles until disease progression or unacceptable toxicity (whichever occurs first).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Relapsed Multiple Myeloma

Keywords

Multiple Myeloma

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

792 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Lenalidomide and Dexamethasone (Rd)

Arm Type

Active Comparator

Arm Description

Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.

Arm Title

Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Dexamethasone

Intervention Description

40 mg orally or IV on days 1, 8, 15, 22

Intervention Type

Drug

Intervention Name(s)

Lenalidomide

Other Intervention Name(s)

Revlimid

Intervention Description

25 mg orally on days 1-21

Intervention Type

Drug

Intervention Name(s)

Carfilzomib

Other Intervention Name(s)

PR-171, Kyprolis®

Intervention Description

20 mg/m², 27 mg/m² intravenously

Primary Outcome Measure Information:

Title

Progression-free Survival (PFS)

Description

Time Frame

From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

Secondary Outcome Measure Information:

Title

Overall Survival

Description

Time Frame

From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.

Title

Overall Response Rate

Description

Time Frame

From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

Title

Disease Control Rate

Description

Time Frame

From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

Title

Duration of Response

Description

Time Frame

From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.

Title

Duration of Disease Control

Description

Time Frame

From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.

Title

Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores

Description

Time Frame

Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Symptomatic multiple myeloma Measurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization): Serum M-protein ≥ 0.5 g/dL Urine Bence-Jones protein ≥ 200 mg/24 hours For immunoglobulin A (IgA) patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL) Prior treatment with at least one, but no more than three, regimens for multiple myeloma Documented relapse or progressive disease on or after any regimen Achieved a response to at least one prior regimen Age ≥ 18 years Life expectancy ≥ 3 months Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Adequate hepatic function, with serum alanine aminotransferase (ALT) ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 21 days prior to randomization Absolute neutrophil count ≥ 1.0 × 10^9/L within 21 days prior to randomization Hemoglobin ≥ 8 g/dL (80 g/L) within 21 days prior to randomization Platelet count ≥ 50 × 10^9/L (≥ 30 × 10^9/L if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization Creatinine clearance (CrCl) ≥ 50 mL/minute within 21 days prior to randomization Written informed consent in accordance with federal, local, and institutional guidelines Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception Male subjects must agree to practice contraception Exclusion Criteria: If previously treated with bortezomib (alone or in combination), progression during treatment If previously treated with a lenalidomide and dexamethasone (len/dex) combination: Progression during the first 3 months of initiating treatment Any progression during treatment if the len/dex combination was the subject's most recent line of therapy Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects intolerant to bortezomib are not excluded Prior carfilzomib treatment POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) Waldenström's macroglobulinemia or IgM myeloma Plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential) Chemotherapy or investigational agent within 3 weeks prior to randomization or antibody therapy within 6 weeks prior to randomization Radiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior to randomization; localized radiotherapy to a single site within 7 days prior to randomization Corticosteroid therapy at a dose equivalent to dexamethasone > 4 mg/day within 21 days prior to randomization Pregnant or lactating females Major surgery within 21 days prior to randomization Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization Known human immunodeficiency virus infection Active hepatitis B or C infection Myocardial infarction within 4 months prior to randomization, New York Hear Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization Other malignancy, including myelodysplastic syndromes (MDS), within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib) Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment Ongoing graft-vs-host disease Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Organizational Affiliation

Amgen

Official's Role

Study Director

Facility Information:

Facility Name

Mayo Clinic

City

Scottsdale

State/Province

Arizona

ZIP/Postal Code

85259

Country

United States

Facility Name

Providence St. Joseph Medical Center

City

Burbank

State/Province

California

ZIP/Postal Code

91505

Country

United States

Facility Name

St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare

City

Santa Rosa

State/Province

California

ZIP/Postal Code

94503

Country

United States

Facility Name

Stanford University

City

Stanford

State/Province

California

ZIP/Postal Code

94305

Country

United States

Facility Name

Colorado Blood Cancer Institute

City

Denver

State/Province

Colorado

ZIP/Postal Code

80218

Country

United States

Facility Name

Cancer and Blood Disease Center

City

Lecanto

State/Province

Florida

ZIP/Postal Code

34461

Country

United States

Facility Name

Rush University Medical Center

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60612

Country

United States

Facility Name

Indiana University Health Melvin and Bren Simon Cancer Center

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46202

Country

United States

Facility Name

University of Kansas Cancer Center

City

Kansas City

State/Province

Kansas

ZIP/Postal Code

66160

Country

United States

Facility Name

The University of Michigan - Comprehensive Cancer Center

City

Ann Arbor

State/Province

Michigan

ZIP/Postal Code

48109

Country

United States

Facility Name

Mayo Clinic

City

Rochester

State/Province

Minnesota

ZIP/Postal Code

55905

Country

United States

Facility Name

John Theurer Cancer Center at Hackensack University Medical Center

City

Hackensack

State/Province

New Jersey

ZIP/Postal Code

07601

Country

United States

Facility Name

NYU Clinical Cancer Center

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Facility Name

Weill Cornell Medical College

City

New York

State/Province

New York

ZIP/Postal Code

10021

Country

United States

Facility Name

Associates in Oncology and Hematology

City

Chattanooga

State/Province

Tennessee

ZIP/Postal Code

37404

Country

United States

Facility Name

The Don & Sybil Harrington Cancer Center

City

Amarillo

State/Province

Texas

ZIP/Postal Code

79106

Country

United States

Facility Name

Baylor Sammons Cancer Center

City

Dallas

State/Province

Texas

ZIP/Postal Code

75246

Country

United States

Facility Name

UT Southwestern Medical Center at Dallas

City

Dallas

State/Province

Texas

ZIP/Postal Code

75390-8565

Country

United States

Facility Name

The University of Texas, MD Anderson Cancer Center

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

Scott and White Memorial Hospital

City

Temple

State/Province

Texas

ZIP/Postal Code

76508

Country

United States

Facility Name

Fred Hutchinson Cancer Research Center

City

Seattle

State/Province

Washington

ZIP/Postal Code

98109

Country

United States

Facility Name

Froedtert & Medical College of Wisconsin

City

Milwaukee

State/Province

Wisconsin

ZIP/Postal Code

53226

Country

United States

Facility Name

Medizinische Universitat Wien

City

Wien

ZIP/Postal Code

1090

Country

Austria

Facility Name

Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie

City

Wien

ZIP/Postal Code

1171

Country

Austria

Facility Name

Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg

City

Antwerpen

ZIP/Postal Code

2060

Country

Belgium

Facility Name

AZ Sint-Jan AV

City

Brugge

ZIP/Postal Code

8000

Country

Belgium

Facility Name

UZ Brussel

City

Brussels

ZIP/Postal Code

1090

Country

Belgium

Facility Name

Institut Jules Bordet

City

Bruxelles

ZIP/Postal Code

1000

Country

Belgium

Facility Name

Cliniques Universitaires Saint-Luc

City

Bruxelles

ZIP/Postal Code

1200

Country

Belgium

Facility Name

UZ Leuven

City

Leuven

ZIP/Postal Code

3000

Country

Belgium

Facility Name

University Multiprofile Hospital for Active Treatment, "Dr. Georgi Stranski"

City

Pleven

ZIP/Postal Code

5800

Country

Bulgaria

Facility Name

University Multiprofile Hospital for Active Treatment "Sveti Georgi"

City

Plovdiv

ZIP/Postal Code

4002

Country

Bulgaria

Facility Name

Military Medical Academy Multiprofile Hospital for Active Treatment

City

Sofia

ZIP/Postal Code

1606

Country

Bulgaria

Facility Name

Specialized Hospital for Active Treatment of Hematological Diseases

City

Sofia

ZIP/Postal Code

1756

Country

Bulgaria

Facility Name

Multiprofile Hospital for Active Treatment "Sveta Marina"

City

Varna

ZIP/Postal Code

9010

Country

Bulgaria

Facility Name

Tom Baker Cancer Centre

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2N 4N2

Country

Canada

Facility Name

University of Alberta, Cross Cancer Institute

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 1Z2

Country

Canada

Facility Name

Vancouver General Hospital

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V5Z 1M9

Country

Canada

Facility Name

Cancer Care Manitoba

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R3E 0V9

Country

Canada

Facility Name

General Hospital, Health Sciences Centre

City

St John's

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1B 3V6

Country

Canada

Facility Name

Princess Margaret Hospital

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5G 2M9

Country

Canada

Facility Name

McGill University Health Center, Royal Victoria Hospital

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H3A 1A1

Country

Canada

Facility Name

Sir Mortimer B. Davis - Jewish General Hospital

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H3T 1E2

Country

Canada

Facility Name

University Hospital Brno, Department of Internal Medicine - Hematooncology

City

Brno

ZIP/Postal Code

625 00

Country

Czechia

Facility Name

University Hospital Hradec Kralove

City

Hradec Kralove

ZIP/Postal Code

500 05

Country

Czechia

Facility Name

University Hospital Olomouc

City

Olomouc

ZIP/Postal Code

775 20

Country

Czechia

Facility Name

University Hospital Kralovske Vinohrady - Prague

City

Praha 10

ZIP/Postal Code

100 34

Country

Czechia

Facility Name

General University Hospital Prague

City

Praha 2

ZIP/Postal Code

128 08

Country

Czechia

Facility Name

Hospital Antoine Beclere

City

Clamart

ZIP/Postal Code

92140

Country

France

Facility Name

Clinique Victor Hugo - Centre Jean Bernard

City

Le Mans

ZIP/Postal Code

72000

Country

France

Facility Name

Hopital Claude Huriez

City

Lille

ZIP/Postal Code

59037

Country

France

Facility Name

CH de Mulhouse, Hopital Emile Muller

City

Mulhouse

ZIP/Postal Code

68070

Country

France

Facility Name

CHU Nantes Hotel Dieu

City

Nantes

ZIP/Postal Code

44093

Country

France

Facility Name

Hopital Saint-Antoine

City

Paris

ZIP/Postal Code

75012

Country

France

Facility Name

Groupe Hospitalier Necker - Enfants Malades

City

Paris

ZIP/Postal Code

75015

Country

France

Facility Name

Cancer Institut Universitaire de Toulouse-Oncopole (iUCT)

City

Toulouse

ZIP/Postal Code

31100

Country

France

Facility Name

Hopitaux de Brabois

City

Vandoeuvre-Les-Nancy

ZIP/Postal Code

54511

Country

France

Facility Name

University of Dusseldorf

City

Dusseldorf

ZIP/Postal Code

40225

Country

Germany

Facility Name

Krankenhaus Nordwest

City

Frankfurt am Main

ZIP/Postal Code

60488

Country

Germany

Facility Name

University of Hamburg-Eppendorf

City

Hamburg

ZIP/Postal Code

20246

Country

Germany

Facility Name

Universitat Heidelberg

City

Heidelberg

ZIP/Postal Code

69120

Country

Germany

Facility Name

Stiftungsklinikum Mittelrhein

City

Koblenz

ZIP/Postal Code

56068

Country

Germany

Facility Name

LMU Klinikum der Universitat

City

Munchen

ZIP/Postal Code

81377

Country

Germany

Facility Name

Universitatsklinikum Munster

City

Munster

ZIP/Postal Code

48129

Country

Germany

Facility Name

Universitatsklinikum Wurzburg

City

Wurzburg

ZIP/Postal Code

97080

Country

Germany

Facility Name

Alexandra Hospital

City

Athens

ZIP/Postal Code

11528

Country

Greece

Facility Name

University General Hospital of Patras

City

Patras

ZIP/Postal Code

26500

Country

Greece

Facility Name

St. Istvan and St. Laszlo Hospital of Budapest

City

Budapest

ZIP/Postal Code

H-1097

Country

Hungary

Facility Name

University of Debrecen, Medical and Health Science Center

City

Debrecen

ZIP/Postal Code

H-4032

Country

Hungary

Facility Name

Petz Aladar County Teaching Hospital

City

Gyor

ZIP/Postal Code

H-9032

Country

Hungary

Facility Name

Bekes County Pandy Kalman Hospital

City

Gyula

ZIP/Postal Code

H-5700

Country

Hungary

Facility Name

Kaposi Mor County Teaching Hospital

City

Kaposvar

ZIP/Postal Code

H-7400

Country

Hungary

Facility Name

University of Pecs

City

Pecs

ZIP/Postal Code

H-7624

Country

Hungary

Facility Name

University of Szeged, Albert Szent-Gyorgi Clinical Center

City

Szeged

ZIP/Postal Code

H-6720

Country

Hungary

Facility Name

Rambam Medical Center

City

Haifa

ZIP/Postal Code

31096

Country

Israel

Facility Name

Hadassah Medical Center, Ein Kerem

City

Jerusalem

ZIP/Postal Code

91120

Country

Israel

Facility Name

Western Gailee Hospital - Nahariya

City

Nahariya

ZIP/Postal Code

22100

Country

Israel

Facility Name

Rabin Medical Center

City

Petach Tikva

ZIP/Postal Code

49100

Country

Israel

Facility Name

The Chaim Sheba Medical Center

City

Ramat Gan

ZIP/Postal Code

52621

Country

Israel

Facility Name

Kaplan Medical Center

City

Rehovot

ZIP/Postal Code

76100

Country

Israel

Facility Name

Azienda Ospedallera Niguarda Ca Granda

City

Milano

ZIP/Postal Code

20162

Country

Italy

Facility Name

Azienda Ospedllero Maggiore della Carita

City

Novara

ZIP/Postal Code

28100

Country

Italy

Facility Name

Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main

City

Pisa

ZIP/Postal Code

56216

Country

Italy

Facility Name

Ospedale S. Eugenio

City

Roma

ZIP/Postal Code

00144

Country

Italy

Facility Name

Azienda Ospedaliera Citta della Salute e della Scienza di Torino

City

Torino

ZIP/Postal Code

10126

Country

Italy

Facility Name

Erasmus MC, Department of Haematology

City

Rotterdam

ZIP/Postal Code

3015 CE

Country

Netherlands

Facility Name

University Clinical Centre, Department of Hematologii Transplantologii

City

Gdansk

ZIP/Postal Code

80-952

Country

Poland

Facility Name

Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp.

City

Gorzow Wielkopolski

ZIP/Postal Code

66-400

Country

Poland

Facility Name

Independent Public Teaching Hospital of Medical University of Silesia in Katowice

City

Katowice

ZIP/Postal Code

40-027

Country

Poland

Facility Name

Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz

City

Lodz

ZIP/Postal Code

93-510

Country

Poland

Facility Name

Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach

City

Suwalki

ZIP/Postal Code

16-400

Country

Poland

Facility Name

Nicolaus Copernicus Municipal Specialist Hospital

City

Torun

ZIP/Postal Code

87-100

Country

Poland

Facility Name

Maria Sklodowska-Curie Institute of Oncology

City

Warszawa

ZIP/Postal Code

02-781

Country

Poland

Facility Name

Zamojski Non-Public Hospital

City

Zamosc

ZIP/Postal Code

22-400

Country

Poland

Facility Name

Fundeni Clinical Institute, "Stefan Berceanu" Center for Hematology and Bone Marrow Transplantation

City

Bucharest

ZIP/Postal Code

022328

Country

Romania

Facility Name

Coltea Clinical Hospital

City

Bucharest

ZIP/Postal Code

030-171

Country

Romania

Facility Name

Bucharest University Emergency Hospital

City

Bucharest

ZIP/Postal Code

050098

Country

Romania

Facility Name

Regional Institute of Iasi

City

Iasi

ZIP/Postal Code

700483

Country

Romania

Facility Name

State Medical Institution Komi Republican Oncological Center

City

Syktyvkar

State/Province

Komi Republic

ZIP/Postal Code

167904

Country

Russian Federation

Facility Name

First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia

City

Izhevsk

ZIP/Postal Code

426039

Country

Russian Federation

Facility Name

Federal State Budgetary Scientific Institution: N.N. Blokhin Russian Cancer Research Center

City

Moscow

ZIP/Postal Code

115478

Country

Russian Federation

Facility Name

Moscow State Medical Institution Municipal City Clinical Hospital n.a. S.P. Botkin

City

Moscow

ZIP/Postal Code

125101

Country

Russian Federation

Facility Name

Federal State Budget Institution: Hematology Research Center under MoH

City

Moscow

ZIP/Postal Code

125167

Country

Russian Federation

Facility Name

FSBI: Russian Research Institute of Hematology and Blood Transfusion under the Ferderal Agency for M&B

City

St. Petersburg

ZIP/Postal Code

191024

Country

Russian Federation

Facility Name

State Higher Educational Institution: St Petersburg State Medical University n.a.I.P Pavlov

City

St. Petersburg

ZIP/Postal Code

197022

Country

Russian Federation

Facility Name

SHEI: First St. Petersburg State Medical University N.a.I.P Pavlov under MoH, Clinic of Bone Marrow Transplant

City

St. Petersburg

ZIP/Postal Code

197101

Country

Russian Federation

Facility Name

Federal State Budget Institute: Federal Almalov Medical Research Centre under Ministry of Healthcare

City

St. Petersburg

ZIP/Postal Code

197341

Country

Russian Federation

Facility Name

Clinical Center of Serbia, Clinic of Hematology

City

Belgrade

ZIP/Postal Code

11000

Country

Serbia

Facility Name

Clinical Hospital Center Bezanijska Kosa

City

Belgrade

ZIP/Postal Code

11000

Country

Serbia

Facility Name

Military Medical Academy, Clinic of Hematology

City

Belgrade

ZIP/Postal Code

11000

Country

Serbia

Facility Name

Clinical Center Nis, Clinic of Hematology

City

Nis

ZIP/Postal Code

18 000

Country

Serbia

Facility Name

Clinical Center of Vojvodina, Clinic of Hematology

City

Novi Sad

ZIP/Postal Code

21 000

Country

Serbia

Facility Name

Hospital Universitario Germans Trias i Pujol

City

Badalona

ZIP/Postal Code

08916

Country

Spain

Facility Name

Hospital Clinic I Provincial

City

Barcelona

ZIP/Postal Code

08036

Country

Spain

Facility Name

Hospital Universitario de Salamanca

City

Salamanca

ZIP/Postal Code

37007

Country

Spain

Facility Name

Hospital Donostia

City

San Sebastian

ZIP/Postal Code

20014

Country

Spain

Facility Name

Hospital Universitario y Politeecnico La Fe

City

Valencia

ZIP/Postal Code

46026

Country

Spain

Facility Name

Hospital Universitario Miguel Servet

City

Zaragoza

ZIP/Postal Code

50009

Country

Spain

Facility Name

Sahlgrenska Universitetssjukhuset

City

Goteborg

ZIP/Postal Code

SE-41345

Country

Sweden

Facility Name

Karolinska Universitetsjukhuset i Huddinge

City

Stockholm

ZIP/Postal Code

SE-14186

Country

Sweden

Facility Name

Karolinska Universitetssjukhuset Solna, Hematologiskt Centrum

City

Stockholm

ZIP/Postal Code

SE-17176

Country

Sweden

Facility Name

St. Bartholomew's Hospital

City

London

ZIP/Postal Code

EC1A 7BE

Country

United Kingdom

Facility Name

Royal Free Hampstead

City

London

ZIP/Postal Code

NW3 2QG

Country

United Kingdom

Facility Name

St. Georges Hospital

City

London

ZIP/Postal Code

SW17 0QT

Country

United Kingdom

Facility Name

Nottingham University Hospitals (City Campus)

City

Nottingham

ZIP/Postal Code

NG5 1PB

Country

United Kingdom

Facility Name

Royal Marsden Hospital

City

Sutton

ZIP/Postal Code

SM2 5PT

Country

United Kingdom

Facility Name

The Royal Wolverhampton Hospital NHS Trust

City

Wolverhampton

ZIP/Postal Code

WV10 OQP

Country

United Kingdom

12. IPD Sharing Statement

Citations:

PubMed Identifier

29615082

Citation

Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018 Apr 4;11(1):49. doi: 10.1186/s13045-018-0583-7.

Results Reference

background

PubMed Identifier

27439911

Citation

Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20.

Results Reference

background

PubMed Identifier

28430175

Citation

Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.

Results Reference

background

PubMed Identifier

28211560

Citation

Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17.

Results Reference

background

PubMed Identifier

27224006

Citation

Jakubowiak AJ, Campioni M, Benedict A, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi S. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016 Nov;19(11):1061-1074. doi: 10.1080/13696998.2016.1194278. Epub 2016 Jun 16.

Results Reference

background

PubMed Identifier

27601539

Citation

Stewart AK, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648.

Results Reference

background

PubMed Identifier

29991494

Citation

Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.

Results Reference

background

PubMed Identifier

33166401

Citation

Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos MA. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv. 2020 Nov 10;4(21):5449-5459. doi: 10.1182/bloodadvances.2020001965.

Results Reference

background

PubMed Identifier

28439109

Citation

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017 Dec;31(12):2630-2641. doi: 10.1038/leu.2017.122. Epub 2017 Apr 25.

Results Reference

background

PubMed Identifier

30287200

Citation

Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):9-22. doi: 10.1016/j.clml.2018.08.016. Epub 2018 Sep 5.

Results Reference

background

PubMed Identifier

29446103

Citation

Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

Results Reference

background

PubMed Identifier

29341834

Citation

Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17.

Results Reference

background

PubMed Identifier

33067574

Citation

Weisel K, Mateos MV, Gay F, Delforge M, Cook G, Szabo Z, Desgraz R, DeCosta L, Moreau P. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia. 2021 Jun;35(6):1732-1744. doi: 10.1038/s41375-020-01049-5. Epub 2020 Oct 16.

Results Reference

background

PubMed Identifier

25482145

Citation

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.

Results Reference

derived

Links:

URL

http://www.amgentrials.com

Description

AmgenTrials clinical trials website

Learn more about this trial

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

We'll reach out to this number within 24 hrs